332 related articles for article (PubMed ID: 22516966)
1. Evidence for upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors.
Lai F; Jiang CC; Farrelly ML; Zhang XD; Hersey P
Melanoma Res; 2012 Jun; 22(3):244-51. PubMed ID: 22516966
[TBL] [Abstract][Full Text] [Related]
2. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.
Paraiso KH; Haarberg HE; Wood E; Rebecca VW; Chen YA; Xiang Y; Ribas A; Lo RS; Weber JS; Sondak VK; John JK; Sarnaik AA; Koomen JM; Smalley KS
Clin Cancer Res; 2012 May; 18(9):2502-14. PubMed ID: 22351686
[TBL] [Abstract][Full Text] [Related]
3. Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS.
Jiang CC; Lai F; Tay KH; Croft A; Rizos H; Becker TM; Yang F; Liu H; Thorne RF; Hersey P; Zhang XD
Cell Death Dis; 2010 Sep; 1(9):e69. PubMed ID: 21364673
[TBL] [Abstract][Full Text] [Related]
4. The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance.
Wroblewski D; Mijatov B; Mohana-Kumaran N; Lai F; Gallagher SJ; Haass NK; Zhang XD; Hersey P
Carcinogenesis; 2013 Feb; 34(2):237-47. PubMed ID: 23087082
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.
Menzies AM; Wilmott JS; Drummond M; Lo S; Lyle M; Chan MM; Thompson JF; Guminski A; Carlino MS; Scolyer RA; Kefford RF; Long GV
Cancer; 2015 Nov; 121(21):3826-35. PubMed ID: 26218930
[TBL] [Abstract][Full Text] [Related]
6. Overcoming metastatic melanoma with BRAF inhibitors.
Hong S; Hong S; Han SB
Arch Pharm Res; 2011 May; 34(5):699-701. PubMed ID: 21656352
[TBL] [Abstract][Full Text] [Related]
7. Long-term effects of BRAF inhibitors in melanoma treatment: friend or foe?
Sloot S; Fedorenko IV; Smalley KS; Gibney GT
Expert Opin Pharmacother; 2014 Apr; 15(5):589-92. PubMed ID: 24456413
[TBL] [Abstract][Full Text] [Related]
8. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression.
Paraiso KH; Xiang Y; Rebecca VW; Abel EV; Chen YA; Munko AC; Wood E; Fedorenko IV; Sondak VK; Anderson AR; Ribas A; Palma MD; Nathanson KL; Koomen JM; Messina JL; Smalley KS
Cancer Res; 2011 Apr; 71(7):2750-60. PubMed ID: 21317224
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A
J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304
[TBL] [Abstract][Full Text] [Related]
10. [New treatment options for metastatic melanoma].
Tietze JK; Berking C
Dtsch Med Wochenschr; 2014 Jul; 139(28-29):1462-7. PubMed ID: 24983194
[No Abstract] [Full Text] [Related]
11. Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor.
Curry JL; Falchook GS; Hwu WJ; Torres-Cabala CA; Duvic M; Tetzlaff MT; Prieto VG
Am J Dermatopathol; 2013 Feb; 35(1):125-8. PubMed ID: 22878367
[TBL] [Abstract][Full Text] [Related]
12. RAF inhibition overcomes resistance to TRAIL-induced apoptosis in melanoma cells.
Berger A; Quast SA; Plötz M; Kuhn NF; Trefzer U; Eberle J
J Invest Dermatol; 2014 Feb; 134(2):430-440. PubMed ID: 23955071
[TBL] [Abstract][Full Text] [Related]
13. Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1.
Wang YF; Jiang CC; Kiejda KA; Gillespie S; Zhang XD; Hersey P
Clin Cancer Res; 2007 Aug; 13(16):4934-42. PubMed ID: 17652623
[TBL] [Abstract][Full Text] [Related]
14. A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1.
Liu Y; Xie M; Song T; Sheng H; Yu X; Zhang Z
Pigment Cell Melanoma Res; 2015 Mar; 28(2):161-70. PubMed ID: 25324174
[TBL] [Abstract][Full Text] [Related]
15. BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma.
Shao Y; Aplin AE
Cell Death Differ; 2012 Dec; 19(12):2029-39. PubMed ID: 22858545
[TBL] [Abstract][Full Text] [Related]
16. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.
Shi H; Hugo W; Kong X; Hong A; Koya RC; Moriceau G; Chodon T; Guo R; Johnson DB; Dahlman KB; Kelley MC; Kefford RF; Chmielowski B; Glaspy JA; Sosman JA; van Baren N; Long GV; Ribas A; Lo RS
Cancer Discov; 2014 Jan; 4(1):80-93. PubMed ID: 24265155
[TBL] [Abstract][Full Text] [Related]
17. Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients.
Hecht M; Zimmer L; Loquai C; Weishaupt C; Gutzmer R; Schuster B; Gleisner S; Schulze B; Goldinger SM; Berking C; Forschner A; Clemens P; Grabenbauer G; Müller-Brenne T; Bauch J; Eich HT; Grabbe S; Schadendorf D; Schuler G; Keikavoussi P; Semrau S; Fietkau R; Distel LV; Heinzerling L
Ann Oncol; 2015 Jun; 26(6):1238-1244. PubMed ID: 25762352
[TBL] [Abstract][Full Text] [Related]
18. Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM.
Rohrbeck L; Gong JN; Lee EF; Kueh AJ; Behren A; Tai L; Lessene G; Huang DC; Fairlie WD; Strasser A; Herold MJ
Cell Death Differ; 2016 Dec; 23(12):2054-2062. PubMed ID: 27689874
[TBL] [Abstract][Full Text] [Related]
19. Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue".
Jarkowski A; Norris L; Trinh VA
Ann Pharmacother; 2014 Nov; 48(11):1456-68. PubMed ID: 25056920
[TBL] [Abstract][Full Text] [Related]
20. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.
Azimi A; Tuominen R; Costa Svedman F; Caramuta S; Pernemalm M; Frostvik Stolt M; Kanter L; Kharaziha P; Lehtiö J; Hertzman Johansson C; Höiom V; Hansson J; Egyhazi Brage S
Cell Death Dis; 2017 Aug; 8(8):e3029. PubMed ID: 29048432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
